Skip to main content
PMC home page
World Journal of Gastroenterology logoLink to World Journal of Gastroenterology
editorial
. 2010 Aug 14;16(30):3743–3744. doi: 10.3748/wjg.v16.i30.3743

Gastroesophageal reflux disease: From heartburn to cancer

Marco G Patti 1,2, Irving Waxman 1,2
PMCID: PMC2921083  PMID: 20698034

Abstract

About 10%-15% of patients with gastroesophageal reflux disease develop Barrett’s esophagus. This is considered a premalignant condition because it can progress from metaplasia to high-grade dysplasia, and eventually to adenocarcinoma. Recently, major advances have been made in the endoscopic treatment of Barrett’s esophagus, therefore limiting the role of surgery in the treatment of this disease.

Keywords: Gastroesophageal reflux disease, Barrett’s esophagus, Esophageal adenocarcinoma, Laparoscopic fundoplication, Radiofrequency ablation, Esophageal endoscopic mucosal resection, Minimally invasive esophagectomy

Gastroesophageal reflux disease affects an estimated 20% of the population in the United States. About 10%-15% of patients with gastroesophageal reflux disease develop Barrett’s esophagus, which eventually can progress to adenocarcinoma, which is currently the fastest growing cancer in the United States. It is recognized that adenocarcinoma is in most cases the end stage of a sequence of events whereby the squamous esophageal epithelium is initially replaced by columnar epithelium without dysplasia. Subsequently, the metaplastic epithelium can progress to low- and high-grade dysplasia and eventually cancer[1-3].

This symposium addresses some key questions in the treatment of this disease process. The pathophysiology and diagnosis of the disease are reviewed, particularly in morbidly obese patients[4-10]. Based on the pathophysiology, the treatment of metaplasia is discussed. Special attention has been placed on new treatment modalities such as radiofrequency ablation and endoscopic mucosal resection, which have revolutionized the treatment of high-grade dysplasia and intramucosal carcinoma[11-16]. The remaining indications for esophagectomy in these cases are discussed[17]. Finally, we have reviewed what to do when invasive cancer is present, discussing the role of neoadjuvant therapy[18-20], the type of esophageal resection (trans-hiatal versus trans-thoracic)[21,22], and the current data available about minimally invasive esophagectomy[23,24]. The authors are both experts dedicated to the treatment of patients with esophageal disorders and have published extensively on these topics.

Footnotes

S- Editor Wang YR L- Editor Kerr C E- Editor Lin YP

References

  • 1.Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500–1511. doi: 10.1053/gast.2002.32978. [DOI] [PubMed] [Google Scholar]
  • 2.Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146. doi: 10.1093/jnci/dji024. [DOI] [PubMed] [Google Scholar]
  • 3.Prach AT, MacDonald TA, Hopwood DA, Johnston DA. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet. 1997;350:933. doi: 10.1016/S0140-6736(05)63269-2. [DOI] [PubMed] [Google Scholar]
  • 4.Kahrilas PJ. Anatomy and physiology of the gastroesophageal junction. Gastroenterol Clin North Am. 1997;26:467–486. doi: 10.1016/s0889-8553(05)70307-1. [DOI] [PubMed] [Google Scholar]
  • 5.Herbella FA, Sweet MP, Tedesco P, Nipomnick I, Patti MG. Gastroesophageal reflux disease and obesity. Pathophysiology and implications for treatment. J Gastrointest Surg. 2007;11:286–290. doi: 10.1007/s11605-007-0097-z. [DOI] [PubMed] [Google Scholar]
  • 6.Tamhankar AP, Peters JH, Portale G, Hsieh CC, Hagen JA, Bremner CG, DeMeester TR. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg. 2004;8:890–897; discussion 897-898. doi: 10.1016/j.gassur.2004.08.001. [DOI] [PubMed] [Google Scholar]
  • 7.Herbella FA, Patti MG. Gastroesophageal reflux disease: From pathophysiology to treatment. World J Gastroenterol. 2010;16:3745–3749. doi: 10.3748/wjg.v16.i30.3745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Gawron AJ, Hirano I. Advances in diagnostic testing for gastroesophageal reflux disease. World J Gastroenterol. 2010;16:3750–3756. doi: 10.3748/wjg.v16.i30.3750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Prachand VN, Alverdy JC. Gastroesophageal reflux disease and severe obesity: Fundoplication or bariatric surgery? World J Gastroenterol. 2010;16:3757–3761. doi: 10.3748/wjg.v16.i30.3757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Oh DS, DeMeester SR. Pathophysiology and treatment of Barrett’s esophagus. World J Gastroenterol. 2010;16:3762–3772. doi: 10.3748/wjg.v16.i30.3762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ganz RA, Overholt BF, Sharma VK, Fleischer DE, Shaheen NJ, Lightdale CJ, Freeman SR, Pruitt RE, Urayama SM, Gress F, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc. 2008;68:35–40. doi: 10.1016/j.gie.2007.12.015. [DOI] [PubMed] [Google Scholar]
  • 12.Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288. doi: 10.1056/NEJMoa0808145. [DOI] [PubMed] [Google Scholar]
  • 13.Chennat J, Konda VJ, Ross AS, de Tejada AH, Noffsinger A, Hart J, Lin S, Ferguson MK, Posner MC, Waxman I. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience. Am J Gastroenterol. 2009;104:2684–2692. doi: 10.1038/ajg.2009.465. [DOI] [PubMed] [Google Scholar]
  • 14.Wassenaar EB, Oelschlager BK. Effect of medical and surgical treatment of Barrett’s metaplasia. World J Gastroenterol. 2010;16:3773–3779. doi: 10.3748/wjg.v16.i30.3773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Chennat J, Waxman I. Endoscopic treatment of Barrett’s esophagus: From metaplasia to intramucosal carcinoma. World J Gastroenterol. 2010;16:3780–3785. doi: 10.3748/wjg.v16.i30.3780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Konda VJA, Ferguson MK. Esophageal resection for high-grade dysplasia and intramucosal carcinoma: When and how? World J Gastroenterol. 2010;16:3786–3792. doi: 10.3748/wjg.v16.i30.3786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Greil R, Stein HJ. Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer? Lancet Oncol. 2007;8:189–190. doi: 10.1016/S1470-2045(07)70053-0. [DOI] [PubMed] [Google Scholar]
  • 18.Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2002;183:274–279. doi: 10.1016/s0002-9610(02)00795-x. [DOI] [PubMed] [Google Scholar]
  • 19.Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol. 2010;16:3793–3803. doi: 10.3748/wjg.v16.i30.3793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, Ten Kate FJ, Obertop H, Tilanus HW, van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246:992–1000; discussion 1000-1001. doi: 10.1097/SLA.0b013e31815c4037. [DOI] [PubMed] [Google Scholar]
  • 21.Gasper WJ, Glidden DV, Jin C, Way LW, Patti MG. Has recognition of the relationship between mortality rates and hospital volume for major cancer surgery in California made a difference?: A follow-up analysis of another decade. Ann Surg. 2009;250:472–483. doi: 10.1097/SLA.0b013e3181b47c79. [DOI] [PubMed] [Google Scholar]
  • 22.Barreto JC, Posner MC. Transhiatal versus transthoracic esophagectomy for esophageal cancer. World J Gastroenterol. 2010;16:3804–3810. doi: 10.3748/wjg.v16.i30.3804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Decker G, Coosemans W, De Leyn P, Decaluwé H, Nafteux P, Van Raemdonck D, Lerut T. Minimally invasive esophagectomy for cancer. Eur J Cardiothorac Surg. 2009;35:13–20; discussion 20-21. doi: 10.1016/j.ejcts.2008.09.024. [DOI] [PubMed] [Google Scholar]
  • 24.Herbella FA, Patti MG. Minimally invasive esophagectomy. World J Gastroenterol. 2010;16:3811–3815. doi: 10.3748/wjg.v16.i30.3811. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES